CombiMatrix On Path To Market Genomic Tests For Cancer, Retardation
This article was originally published in The Gray Sheet
Executive Summary
CombiMatrix Molecular Diagnostics (CMD) is looking to file with FDA for market approval of complex gene signature tests for cancer and mental retardation by the end of the year, according to the firm
You may also be interested in...
New Genetic Test Guidance Narrows Focus To Mutation Marker Assays
FDA is narrowing the focus of its proposed guidelines for manufacturers of gene-based tests from its original 2003 draft in response to comments from industry members and scientists, according to a revised 1draft guidance document issued Feb. 9
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.